Cayman Naloxone benzoylhydrazone

ML-364 is a reversible inhibitor of ubiquitin-specific protease 2 (USP2), a deubiquitinase, that has an IC₅₀ value of 1.1 µM in a fluorescence-based assay using di-ubiquitin substrates. It inhibits USP8, which is closely related to USP2, with an IC₅₀ value of 0.95 µM in the same assay. It has no activity at the proteases caspase-6, caspase-7, MMP-1, MMP-9, and USP15 or at 102 kinases in a panel including cell cycle regulators. ML-364 increases cyclin D1 degradation (IC₅₀ = 0.97 µM) in HCT116 colorectal carcinoma cells. It induces arrest of the cell cycle at the G₁ phase in Mino mantle cell lymphoma and HCT116 cells and inhibits proliferation of HCT116 cells (IC₅₀ = 3.6 µM). It also decreases homologous recombination-mediated DNA repair in DR-GFP U2OS cells.

WARNING This product is not for human or veterinary use.